SPDR S&P BIOTECH ETF

No trades

See on Supercharts

Overview

Analysis News Ideas Discussions Seasonals

SSGF chart

Full chart

Key stats

Assets under management (AUM)

‪5.65 B‬ EUR

Fund flows (1Y)

—

Dividend yield (indicated)

0.14%

Discount/Premium to NAV

—

Shares outstanding

‪61.02 M‬

Expense ratio

0.35%

About SPDR S&P BIOTECH ETF

Issuer

State Street Corp.

Brand

SPDR

Home page

us.spdrs.com

Inception date

Jan 31, 2006

Structure

Open-Ended Fund

Index tracked

S&P Biotechnology Select Industry

Management style

Passive

Distributes

Capital Gains

Max ST capital gains rate

39.60%

Max LT capital gains rate

20.00%

Tax on distributions

Qualified dividends

Primary advisor

SSgA Funds Management, Inc.

Distributor

State Street Corp. (Fund Distributor)

XBI provides exposure to US biotech stocks, as defined by GICS, from a universe that invests across the market-cap spectrum. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market-cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly.